Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- James E. Butrynski, MD
Dana-Farber Cancer Institute
Principal Investigator - Nguyen Binh Bui, MD
Institut Bergonié
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
43 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medical University Vienna
Vienna, Austria
- Cliniques Universitaires St. Luc
Brussels, Belgium
- Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, Belgium
- U.Z. Gasthuisberg
Leuven, Belgium
- Aarhus University Hospital
Aarhus, Denmark
- Herlev Hospital - University Copenhagen
Herlev, Denmark
- Institut Bergonie
Bordeaux, France
- Centre Georges-Francois-Leclerc
Dijon, France
- Centre Oscar Lambret
Lille, France
- Centre Leon Berard
Lyon, France
- Assistance Publique - Hôpitaux de Marseille - Hôpital de la Timone
Marseille, France
- Institut de Cancerologie de L'Ouest (ico) - Centre Rene Gauducheau
Nantes - Saint Herblain, France
- Institut Curie
Paris, France
- Institut Gustave Roussy
Villejuif, France
- Helios Klinikum Bad Saarow
Bad Saarow, Germany
- Universitaetsklinikum Koeln
Cologne, Germany
- Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
- Universitaets-Krankenhaus Eppendorf
Hamburg, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitaetsmedizin Mannheim
Mannheim, Germany
- Klinikum Grosshadern Ludwig-Maximilians Univ. Muenchen
München, Germany
- Military Hospital - State Health Centre
Budapest, Hungary
- the Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Amsterdam, Netherlands
- University Medical Center Groningen
Groningen, Netherlands
- Leiden University Medical Centre
Leiden, Netherlands
- Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
- Erasmus Mc - Daniel Den Hoed Cancer Center
Rotterdam, Netherlands
- Maria Sklodowska-Curie Memorial Cancer Centre
Warsaw, Poland
- National Cancer Institute
Bratislava, Slovakia
- Hospital General Vall D'Hebron
Barcelona, Spain
- Hospital Universitario San Carlos
Madrid, Spain
- Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
- Nhs Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
- Christie Nhs Foundation Trust
Manchester, United Kingdom
- Nottingham University Hospitals Nhs Trust - City Hospital Campus
Nottingham, United Kingdom
- Sarcoma Oncology Center
Santa Monica, California, United States
- Stanford Hospital and Clinics
Stanford, California, United States
- Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States
- Dana Farber Institute
Boston, Massachusetts, United States
- Massachussets General Hospital
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2011
- Primary completion
- 30 Jun 2013
- Completion
- 30 Jun 2015
- Last update posted
- 8 Aug 2014
- Registered enrollment
- 133
- Registry id
- NCT01189253
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.